Article info
Poster Presentations
P-30 IL-16 blood levels and combined polymorphism of CCL11 and IL-16 are the biomarkers to select oxycodone for cancer pain management
Citation
P-30 IL-16 blood levels and combined polymorphism of CCL11 and IL-16 are the biomarkers to select oxycodone for cancer pain management
Publication history
- First published September 5, 2024.
Online issue publication
September 05, 2024
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.